Oak Associates’s AstraZeneca AZN Stock Holding History

Oak Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,600	Closed	-$534K	–	165
2018 Q2	$534K	Sell	7,600 -16,900	-69%	-$1.22M	0.04%	128
2018 Q1	$1.71M	Sell	24,500 -2,950	-11%	-$204K	0.12%	89
2017 Q4	$1.91M	Buy	+27,450	New	+$1.85M	0.14%	89
2016 Q4	–	Sell	-16,350	Closed	-$926K	–	169
2016 Q3	$926K	Sell	16,350 -2,150	-12%	-$141K	0.1%	115
2016 Q2	$1.12M	Hold	18,500	–	–	0.13%	104
2016 Q1	$1.04M	Sell	18,500 -2,550	-12%	-$153K	0.13%	104
2015 Q4	$1.43M	Sell	21,050 -12,550	-37%	-$823K	0.17%	99
2015 Q3	$2.14M	Sell	33,600 -9,100	-21%	-$599K	0.28%	78
2015 Q2	$2.72M	Hold	42,700	–	–	0.33%	72
2015 Q1	$2.92M	Hold	42,700	–	–	0.35%	65
2014 Q4	$3M	Hold	42,700	–	–	0.36%	61
2014 Q3	$3.05M	Hold	42,700	–	–	0.38%	60
2014 Q2	$3.17M	Hold	42,700	–	–	0.39%	60
2014 Q1	$2.77M	Hold	42,700	–	–	0.34%	61
2013 Q4	$2.54M	Buy	+42,700	New	+$2.32M	0.27%	68
2013 Q2	$2.07M	Buy	+43,800	New	+$2.23M	0.25%	70

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Oak Associates's AZN Position: Q3 2018 in Review

Oak Associates sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 7,600 shares — an estimated $534K sold.

Oak Associates first reported a position in AZN in Q2 2013 and held it in 16 quarters. The position peaked at $3.17M in Q2 2014. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

Oak Associates reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
Oak Associates sold 7,600 AstraZeneca shares in Q3 2018, an estimated $534K.
Oak Associates first reported a position in AstraZeneca in Q2 2013 and held it in 16 quarters.
Oak Associates's AstraZeneca position peaked at $3.17M in Q2 2014.
544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on Oak Associates's 13F filing for Q3 2018, filed 13 Nov 2018.